Integrated molecular characterization of pediatric soft tissue sarcomas: A report from the COG and CCDI molecular characterization initiative. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Association between targeted cancer drug net health benefit and uptake, patient out-of-pocket spending, and total spending. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...
The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results